This policy describes standards for reviewing clinical information about erectile dysfunction, oral ED medicines and injectable treatment options. A documented qualified medical review is different from editorial source-checking. Publishing this policy does not mean that every EDMedix article has been reviewed or approved by a physician.
Last updated: October 15, 2026
Errors concerning contraindications, treatment indications, drug interactions or injection handling can lead to harmful assumptions. ED content may be encountered by readers seeking a medicine before they have been evaluated for cardiovascular risks or underlying conditions.
A medical review, when carried out by an appropriately qualified professional, should evaluate both the accuracy of the underlying information and how the wording may influence decisions. It complements the Editorial Policy.
An editor can check that a sentence corresponds to a source, that an internal link is canonical and that product names are spelled correctly. Clinical medical review requires competent interpretation of medicine labeling and the implications of particular statements for patient safety.
Neither a lengthy bibliography nor a medical-sounding headline proves professional review. We do not label a page “medically reviewed” simply because a source check was completed.
| Editorial fact-checking | Qualified clinical medical review |
|---|---|
| Verifies citations, dates and product names | Evaluates clinical relevance and possible unsafe interpretations |
| Checks formatting, headings and accuracy of quoted records | Checks indications, contraindications and medication interactions |
| Separates product identity from marketing claims | Checks patient-safety implications and limits of evidence |
| May occur during normal content preparation | Requires an actual competent professional and review record |
The reviewer should confirm the exact active ingredient, finished product, indicated patient population, tablet or injection form, safety warnings, significant drug interactions and any statements about frequency or use. A review also tests whether study findings are translated faithfully into plain English.
It should identify any text that may encourage unsupervised dose escalation, mixing PDE5 inhibitors, use with nitrates or substitution of foreign-market brands for U.S.-approved prescriptions.
Priority topics include sildenafil interactions, tadalafil interactions, vardenafil interactions, sildenafil side effects and tadalafil side effects. Product-comparison pages also warrant attention to misleading efficacy or onset interpretations.
A list of higher-risk pages is not evidence that each has already been reviewed by an individual clinician. Review status belongs to a documented content version.
An appropriate review must check class-related contraindications for PDE5 inhibitors, especially organic nitrates and riociguat. It should avoid inventing safe home waiting periods for emergency medicines or encouraging patients to stop prescribed cardiovascular therapy.
ED may signal underlying vascular disease. The reviewer should consider whether language about cardiovascular suitability appropriately directs individual assessment to clinicians rather than creating automatic eligibility from a shopping questionnaire.
Vardenafil has QT-related precautions concerning congenital long QT syndrome and selected antiarrhythmics. Its conventional film-coated tablet labels and separately authorized ODT labels may also differ in interaction restrictions.
A reviewer should not carry a dose-adjustment statement from one formulation into another without checking the product’s own label. See vardenafil ODT for the difference between 10 mg orally disintegrating and 10 mg film-coated products.
Tadalafil may be prescribed for ED under daily or as-needed frameworks, and its U.S. product labels also address BPH and combined ED/BPH contexts. The clinical review should identify which indication and regimen an article discusses.
Kidney or liver function, interacting drugs and the potential for persistent exposure may change prescribing restrictions. A reviewer should ensure exceptions in U.S. labeling are not erased by a simplistic “one tablet per day” summary. See tadalafil dosage.
Intracavernosal alprostadil requires supervised treatment initiation and patient training before appropriate home use. Caverject vial presentations, Caverject Impulse systems and Edex have different device or preparation instructions and cannot be treated as identical kits.
The reviewer should ensure descriptions of prolonged erections, penile abnormalities, bleeding, training and product status are accurate. Our educational articles do not provide a step-by-step injection procedure for independent treatment.
A clinical result must be tied to the trial endpoint and population. Time to maximum plasma concentration is not automatically time to a useful erection; elimination half-life is not a personal guarantee of response duration.
A professional reviewer should distinguish a controlled trial’s results from brand advertising and resist implying that one medicine is universally more effective based on different studies conducted under different conditions.
Product identity and regulatory authorization are central clinical context. FDA approval or therapeutic equivalence should be attributed to the precise approved product, not inferred from a shared ingredient or a foreign catalog.
If an India-market brand is discussed, reviewer attention should focus on potential confusion between plain PDE5 products and combination tablets containing dapoxetine, and on the risk of treating seller claims as safe medication guidance.
Clinical review should ensure that website language does not promise a prescription, imply a doctor–patient relationship from reading a page or describe a telehealth questionnaire as a substitute for all necessary assessment.
The distinction between the prescriber, the dispensing pharmacist, a third-party referral service and EDMedix as an informational publisher should remain clear.
A reviewer should be a real qualified professional with expertise appropriate to the subject, such as a licensed physician or pharmacist with relevant clinical knowledge. Medical or pharmacy licensing and claimed affiliations should be checked where applicable.
Specialized qualifications matter: a title alone does not qualify someone to review every topic. Our Medical Reviewer page describes identity verification and attribution standards.
For a completed review, an appropriate record should identify the actual reviewer, the article or version examined, the review date, the scope of work, substantive corrections and any relevant conflicts of interest. Reviewer names and credentials should only be displayed when verified and authorized.
This page does not assert that EDMedix currently employs a named physician or that every page has undergone individual professional review. Editorial publication and completed clinical review should not be represented as the same status.
Material changes to FDA labeling, safety communications, approved-product status or clinical evidence can require another review. A revised article should not automatically retain a prior reviewer credit if the relevant content has changed substantially.
Readers may flag an apparently outdated claim using Contact EDMedix. A correction request is reviewed according to the specificity and reliability of its evidence.
Professional review of website content, when performed, is not personalized treatment, prescribing approval, pharmacy accreditation or verification of a supplier’s stock. It does not make any medicine suitable for all readers.
For a medical emergency or symptoms such as chest pain, sudden vision loss or an erection lasting more than four hours, seek urgent medical attention. Do not use the website contact form for immediate clinical help.